Effects of vitamin D as a regulator of androgen intracrinology in LNCAP prostate cancer cells

Diego Cobice, Karl Smith, Paul Thompson, Edna Patricia Rodriguez, Logan Mackay

Research output: Contribution to journalArticle

Abstract

Prostate cancer is initially treated via androgen deprivation therapy (ADT), a highly successful treatment in the initial pursuit of tumor regression, but commonly restricted by the eventual emergence of a more lethal ‘castrate resistant’ form of the disease. Intracrine pathways that utilize dehydroepiandrosterone (DHEA) or other circulatory precursor steroids, are thought to generate relevant levels of growth-stimulating androgens such as testosterone (T) and dihydrotestosterone (DHT). In this study, we explored the capacity of the active vitamin D hormone to interact and elicit changes upon this prostatic intracrine pathway at a metabolic level. We used androgen dependent LNCaP cells cultured under steroid-depleted conditions and assessed the impact of vitamin D-based compounds upon intracrine pathways that convert exogenously added DHEA to relevant metabolites, through Mass Spectrometry (MS). Changes in relevant metabolism-related gene targets were also assessed. Our findings confirm that exposure to vitamin D based compounds, within LNCaP cells, elicits measurable and significant reduction in the intracrine conversion of DHEA to T, DHT and other intermediate metabolites within the androgenic pathway. The aassessment and validation of the biological model and analytical platforms were performed by pharmacological manipulations of the SRD5α and HSD-17β enzymes. The data provides further confirmation for how a vitamin D-based regime may be used to counter intracrine mechanisms contributing to the emergence of castrate-resistant tumors.

LanguageEnglish
Pages579-584
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume519
Issue number3
Early online date16 Sep 2019
DOIs
Publication statusPublished - 12 Nov 2019

Fingerprint

Vitamin D
Androgens
Dehydroepiandrosterone
Prostatic Neoplasms
Cells
Dihydrotestosterone
Metabolites
Tumors
Steroids
Biological Models
Metabolism
Mass spectrometry
Testosterone
Cultured Cells
Mass Spectrometry
Neoplasms
Genes
Hormones
Pharmacology
Enzymes

Keywords

  • Intracrinology
  • Mass spectrometry
  • Metabolism
  • Prostate cancer
  • Vitamin D

Cite this

@article{c74b004e260e4d9597fe66623871e7ee,
title = "Effects of vitamin D as a regulator of androgen intracrinology in LNCAP prostate cancer cells",
abstract = "Prostate cancer is initially treated via androgen deprivation therapy (ADT), a highly successful treatment in the initial pursuit of tumor regression, but commonly restricted by the eventual emergence of a more lethal ‘castrate resistant’ form of the disease. Intracrine pathways that utilize dehydroepiandrosterone (DHEA) or other circulatory precursor steroids, are thought to generate relevant levels of growth-stimulating androgens such as testosterone (T) and dihydrotestosterone (DHT). In this study, we explored the capacity of the active vitamin D hormone to interact and elicit changes upon this prostatic intracrine pathway at a metabolic level. We used androgen dependent LNCaP cells cultured under steroid-depleted conditions and assessed the impact of vitamin D-based compounds upon intracrine pathways that convert exogenously added DHEA to relevant metabolites, through Mass Spectrometry (MS). Changes in relevant metabolism-related gene targets were also assessed. Our findings confirm that exposure to vitamin D based compounds, within LNCaP cells, elicits measurable and significant reduction in the intracrine conversion of DHEA to T, DHT and other intermediate metabolites within the androgenic pathway. The aassessment and validation of the biological model and analytical platforms were performed by pharmacological manipulations of the SRD5α and HSD-17β enzymes. The data provides further confirmation for how a vitamin D-based regime may be used to counter intracrine mechanisms contributing to the emergence of castrate-resistant tumors.",
keywords = "Intracrinology, Mass spectrometry, Metabolism, Prostate cancer, Vitamin D",
author = "Diego Cobice and Karl Smith and Paul Thompson and Rodriguez, {Edna Patricia} and Logan Mackay",
year = "2019",
month = "11",
day = "12",
doi = "10.1016/j.bbrc.2019.09.059",
language = "English",
volume = "519",
pages = "579--584",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Elsevier",
number = "3",

}

Effects of vitamin D as a regulator of androgen intracrinology in LNCAP prostate cancer cells. / Cobice, Diego; Smith, Karl; Thompson, Paul; Rodriguez, Edna Patricia; Mackay, Logan.

In: Biochemical and Biophysical Research Communications, Vol. 519, No. 3, 12.11.2019, p. 579-584.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of vitamin D as a regulator of androgen intracrinology in LNCAP prostate cancer cells

AU - Cobice, Diego

AU - Smith, Karl

AU - Thompson, Paul

AU - Rodriguez, Edna Patricia

AU - Mackay, Logan

PY - 2019/11/12

Y1 - 2019/11/12

N2 - Prostate cancer is initially treated via androgen deprivation therapy (ADT), a highly successful treatment in the initial pursuit of tumor regression, but commonly restricted by the eventual emergence of a more lethal ‘castrate resistant’ form of the disease. Intracrine pathways that utilize dehydroepiandrosterone (DHEA) or other circulatory precursor steroids, are thought to generate relevant levels of growth-stimulating androgens such as testosterone (T) and dihydrotestosterone (DHT). In this study, we explored the capacity of the active vitamin D hormone to interact and elicit changes upon this prostatic intracrine pathway at a metabolic level. We used androgen dependent LNCaP cells cultured under steroid-depleted conditions and assessed the impact of vitamin D-based compounds upon intracrine pathways that convert exogenously added DHEA to relevant metabolites, through Mass Spectrometry (MS). Changes in relevant metabolism-related gene targets were also assessed. Our findings confirm that exposure to vitamin D based compounds, within LNCaP cells, elicits measurable and significant reduction in the intracrine conversion of DHEA to T, DHT and other intermediate metabolites within the androgenic pathway. The aassessment and validation of the biological model and analytical platforms were performed by pharmacological manipulations of the SRD5α and HSD-17β enzymes. The data provides further confirmation for how a vitamin D-based regime may be used to counter intracrine mechanisms contributing to the emergence of castrate-resistant tumors.

AB - Prostate cancer is initially treated via androgen deprivation therapy (ADT), a highly successful treatment in the initial pursuit of tumor regression, but commonly restricted by the eventual emergence of a more lethal ‘castrate resistant’ form of the disease. Intracrine pathways that utilize dehydroepiandrosterone (DHEA) or other circulatory precursor steroids, are thought to generate relevant levels of growth-stimulating androgens such as testosterone (T) and dihydrotestosterone (DHT). In this study, we explored the capacity of the active vitamin D hormone to interact and elicit changes upon this prostatic intracrine pathway at a metabolic level. We used androgen dependent LNCaP cells cultured under steroid-depleted conditions and assessed the impact of vitamin D-based compounds upon intracrine pathways that convert exogenously added DHEA to relevant metabolites, through Mass Spectrometry (MS). Changes in relevant metabolism-related gene targets were also assessed. Our findings confirm that exposure to vitamin D based compounds, within LNCaP cells, elicits measurable and significant reduction in the intracrine conversion of DHEA to T, DHT and other intermediate metabolites within the androgenic pathway. The aassessment and validation of the biological model and analytical platforms were performed by pharmacological manipulations of the SRD5α and HSD-17β enzymes. The data provides further confirmation for how a vitamin D-based regime may be used to counter intracrine mechanisms contributing to the emergence of castrate-resistant tumors.

KW - Intracrinology

KW - Mass spectrometry

KW - Metabolism

KW - Prostate cancer

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=85072163287&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2019.09.059

DO - 10.1016/j.bbrc.2019.09.059

M3 - Article

VL - 519

SP - 579

EP - 584

JO - Biochemical and Biophysical Research Communications

T2 - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -